Plus a new tenant at Arsenal Yards and 5 companies crack the Boston Globe's Next In Medicine
Advertisement
64 Pleasant Street: Watertown Square Lab & Flex Lease Options
Fall is here, and if you’re looking to network with other life science professionals in Watertown, register for Cambridge Scientific’s Octoberfest on 10/1 here. Before reading on, consider sharing this newsletter with a friend and subscribe to support our work.
Stealth start-up Metamorphic Therapeutics moving to Genesis building, Marrow Therapeutics moving into 100 Forge
Watertown’s 2026 biotech rebound continues apace with two companies pulling permits to move into lab space over the last two weeks.
Metamorphic Therapeutics filed a permit with the City for a lab at the Genesis building (250 Arsenal Place). The company is in stealth and there is not much public information available about their work, but personnel attached to the permit have appear to have experience in the oncology space, so we speculate it may be a new oncology focused company. This is welcome news for the Genesis building, since it lost half its tenants last year when Transition Bio closed their US lab and Day Zero Diagnostics was acquired by BioMerieux and their lab was absorbed into the parent company. Metamorphic will join fellow tenants Souffle Therapeutics, which launched from stealth last year with $200 million in funding, and Seismic Therapeutic, a clinical stage firm developing antibody therapeutics, who's lead program S-4321 is currently in Phase 1 trials for cell-mediated immune diseases.
Marrow Therapeutics also recently filed a permit with the City to open up a lab at 100 Forge at Arsenal Yards. The company currently operates out of the BioLab shared space on Coolidge Ave. Marrow is focusing on developing antibody based therapeutics to treat blood diseases such as sickle cell disease and beta thalassemia. Marrow will join fellow Arsenal Yards tenant Orna Therapeutics in this space, as Orna signed a deal last year with Vertex Pharmaceuticals to develop gene therapeis for both sickle cell disease and beta thalassemia. Recently departed Stratus Therapeutics (Arsenal on the Charles) was also working a therapy for beta thalassemia. 100 Forge has also seen a turnaround this year, wtih Marrow Therapeutics joining Triveni Bio, offsetting the losses of Abata Therapeutics and Affini-t therapeutics last fall.
23 Elm Street offers 66,634 SF of cutting -edge, fully furnished spec lab space, engineered to support scientific innovations and empower research with best-in-class facilities.
Five Watertown biotechs featured on Boston Globe’s Next in Medicine List
On September 15th, the Boston Globe held its 3rd annual Future of Medicine event which they described as “an event at the forefront of medicla innovation.” As part of the event, the Globe partnered with the Harvard Griffin GSAS Biotechnology Club and Nucleate Boston to nominate 35 companies for the Next in Medicine list, which they claim are are “identifying some of the most consequential ideas in biotechnology today.” Five Watertown companies made the list:
Orna Therapeutics (Which was purchased by Eli Lilly earlier this year) and EnPlusOne Bio for their work in RNA therapeutics.
Ethyreal Bio,who is moving to the Arsenal on the Charles, for their work in immunology.
Portal Biosciences for their work on cellular delivery systems.
Tectonic Therapeutic for their work in cardiovascular/cardiometabolic disease.
Read the full Next in Medicine List here
Quick Hits
Arrivals
Ampersand Biomedicines moved into their new lab at 99 Coolidge Ave.
Science/ Clinical News
Prime Medicine, which operates a lab on Arsenal Street, received FDA clearance of their IND for PMA647, designed to correct mutations causing alpha-1 antitrypsin deficiency.
C4 Therapeutics presented new data from their Phase 1 trials of Cemsidomide in combination with Dexamethasone or Elranatamab.
Kestrel Therapeutics was awarded an FDA Fast Track designation for KST-6051, their oral pan-KRAS inhibitor in development for solid tumors.
Business News
Constantiam Biosciences was awarded a $2.5 million grant from the NIH to develop a genetic risk test for Alzheimer’s.
ALS TDI released their 2025 Annual Report.
People
Remix announced Tony Mullin as their Chief People Officer.
Media
LabShare CEO Philip Borden’s was a guest on Mass Bio’s R&D Reimagined Podcast.
That’s all for this week!
